Cryptome completes acquisition of HealthLinx
Advertisement
Cryptome Pharmaceuticals Limited announced that it has completed the acquisition of HealthLinx Pty Ltd. HealthLinx, a privately held company before its acquisition, focuses on biomarkers and the development of diagnostics, with its lead candidates targeting ovarian cancer and complications in pregnancy. This follows the approval by shareholders of the transaction at the extraordinary general meeting.
The all-scrip acquisition has been accompanied by a capital raising of $2 million, which provides a strong funding base for the business, alongside revenue to be generated by the previously announced Dairy Australia contract. The merged entity will be known as HealthLinx Limited (HealthLinx). A new ASX code will be allocated and advised shortly.